FLT3-ITD等位基因比值在高剂量蒽环类联合FLT3抑制剂治疗的AML患者中的预后影响
本研究基于前瞻性BIG-1研究,纳入459例60岁以下初诊AML患者,均接受高剂量蒽环类诱导治疗,2018年起FLT3突变者加用米哚妥林。结果显示FLT3-ITD等位基因比值(AR)与复合完全缓解、总生存、无复发生存及无事件生存均无显著关联;多变量分析仅米哚妥林暴露和不良ELN-2022风险与OS独立相关。
要点
- 在高剂量蒽环类联合米哚妥林治疗背景下,FLT3-ITD AR无独立预后影响。
- 米哚妥林暴露与改善OS独立相关(aHR 0.69)。
- 异基因造血干细胞移植改善无复发生存和无事件生存,但不改善OS。
核心结论
- 在年轻AML患者接受强化蒽环类化疗和米哚妥林治疗的当代实践中,FLT3-ITD AR无独立预后影响。
研究设计与样本
- 前瞻性BIG-1研究纳入459例60岁以下初诊AML患者,均接受高剂量蒽环类诱导治疗,2018年起FLT3突变者加用米哚妥林。
主要发现
- 低AR与高AR的复合完全缓解率分别为81.7%和79.6%(p=0.85)。
- 低AR与高AR的中位OS分别为7.6年和6.9年(p=0.25)。
- 低AR与高AR的中位无复发生存分别为2.0年和1.7年(p=0.50)。
- 低AR与高AR的中位无事件生存分别为1.4年和1.2年(p=0.58)。
- 多变量分析中,米哚妥林暴露(aHR 0.69,95%CI 0.50-0.95,p=0.024)和不良ELN-2022风险(aHR 1.66,95%CI 1.18-2.34,p=0.004)与OS独立相关。
关键数值与推荐
- 异基因造血干细胞移植与改善无复发生存(aHR 0.40,95%CI 0.29-0.55,p<0.001)和无事件生存(aHR 0.37,95%CI 0.27-0.51,p<0.001)相关,但与OS无关。
临床怎么用
- 对于接受高剂量蒽环类联合米哚妥林治疗的年轻AML患者,FLT3-ITD AR可能不再作为独立预后分层依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic value of FLT3 internal tandem duplication (FLT3-ITD) in acute myeloid leukemia (AML) has traditionally been stratified according to the ITD/wild-type allelic ratio (AR) and NPM1 co-mutation status. We evaluated the prognostic impact of FLT3-ITD AR in 459 newly diagnosed AML patients younger than 60 years enrolled in the prospective BIG-1 study, all treated with high-dose anthracycline-based induction. From 2018 onward, midostaurin was added for FLT3-mutated cases. AR was not associated with composite complete remission (81.7% vs. 79.6% in low vs. high AR, p = 0.85), overall survival (OS) (median 7.6 vs. 6.9 years, p = 0.25), relapse-free survival (median 2.0 vs. 1.7 years, p = 0.50), or event-free survival (median 1.4 vs. 1.2 years, p = 0.58). In multivariable analyses, only midostaurin exposure (adjusted hazard ratio [aHR] 0.69, 95% CI 0.50-0.95, p = 0.024) and adverse ELN-2022 risk (aHR 1.66, 95% CI 1.18-2.34, p = 0.004) were independently associated with OS. Allogeneic hematopoietic stem cell transplantation was associated with improved relapse-free (aHR 0.40, 95% CI 0.29-0.55, p < 0.001) and event-free survival (aHR 0.37, 95% CI 0.27-0.51, p < 0.001), but not OS. These results indicate that FLT3-ITD AR has no independent prognostic impact in younger AML patients treated with intensive anthracycline-based chemotherapy and midostaurin in contemporary clinical practice.
引用
- Leclerc M, Audureau E, Duployez N, et al. Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor. Am J Hematol. 2026. PMID: 42934825. doi:10.1002/ajh.70540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。